Some studies found that the presence of miR-195 in fibroblast-derived EVs suppresses the activation of VEGF, CDC42, CDK1, CDK4, CDK6, and CDC25 and is considered to be a new therapeutic target for HCC [117,118]. Here, CDK4 is linked to hepatocellular carcinoma.